Which Indy hospitals do it right the first time?
Medicare data show some county-owned hospitals around Indianapolis scored better than big-name hospitals like IU Health and Community.
J.K. Wall
Articles
Patients get what they pay for
Patients, in spite of what it may feel like, pay only a tiny fraction of the total health care bill directly from their own pockets. It’s no wonder then that prices and good service are hard to find.
SEC accuses Indy cancer firm of being a sham
The SEC says the CEO of locally based biomedical firm Xytos Inc. has committed securities fraud
since 2010 by repeatedly publishing false information to investors about the company. Timothy Cook denies the accusations.
Slower rise in health insurance costs is an illusion
The ‘modest’ 4 percent rise in health insurance premiums, when compared with wages, shows things are getting worse, not better, for health care consumers.
Indiana public health continues slide
It’s fair to say that wellness has never gotten more attention in Indiana than it is now. Trouble is, that attention doesn’t seem to be producing change.
Swapping Obamacare for a single-payer system?
How would a single-payer national health insurance program change the finances for employers, workers, doctors and hospitals?
Healthx using IT to connect insurers to their customers
Health insurance has long been a business-to-business endeavor between insurers, employers, hospitals and doctors. Patients received benefits, but they weren’t really customers. That’s all about to change.
BioCrossroads drops dreams for hospital innovation
In this age of austerity, there’s almost no chance of Indianapolis hospitals creating a Cleveland Clinic-like hub of innovation.
Teachers union could pay $14M to schools under settlement
Funds would cover about half of the money the ISTA Insurance Trust claimed was being held in reserve on behalf of school employees in its health insurance plan.
Symbios collapse snares local investors
Symbios Medical Products LLC filed for Chapter 7 bankruptcy liquidation, costing numerous Indianapolis-area angel investors large sums.
A dose of light reading
Starting with this post, I’m going to periodically give you a peek at my reading list. I’ll highlight reports and reportage that I have found either helpful or provocative. I hope you do, too.
Lilly’s new strategy built around head-to-head drug trials
Lilly has set up not one, not two, but five head-to-head trials of its experimental drug dulaglutide against other leading diabetes therapies. So far, dulaglutide’s record is four wins, no losses.
OrthoIndy channeling Walmart in comeback bid
The local orthopedic surgeons are presenting themselves as low-cost providers in an attempt to reverse growth restrictions imposed by Obamacare.
Expect deja vu: Obamacare won’t fix health care
By and large, Obamacare will leave in place the same major problems in the health care systems that existed before the law was passed—in both Indiana and across the nation.
Cook to unleash wave of ear, nose, throat products
Bloomington-based Cook Medical Inc. recently launched two new products and expects to launch eight to 10 more over the next year.
Board suggested busy Evans let go of AIT
Michael Evans was juggling two companies and two newborn twins when his board of directors suggested it was time for a new CEO of AIT Laboratories. He was replaced by venture capitalist Matt Neff on Monday.
Roche to cut local jobs after diabetes-care sales plunge
Roche’s diabetes care unit, which employs more than 900 in Indianapolis, suffered a 14-percent decline in revenue during the first half of 2013. Roche has reportedly put the unit up for sale.
Already a wreck, the worst is yet to come with Obamacare
Obamacare is destined to fail for one key reason: it will make health insurance cost more and buy less.
Life sciences venture capital dips again
Venture capital surged in the first half of 2012, to $51.6 million in Indiana. But the pace of activity here fell off sharply in the second half of last year, and remained sluggish into 2013.
Relax, rejoice: Obamacare will revive health care
This is the first of three blog posts, each of which will make a compelling case for one of three distinct positions on Obamacare in Indiana: why it will succeed, why it will fail and why it will be a “non-event.”